medigraphic.com

2011, Number 2

<< Back Next >>

Rev Mex Med Repro 2011; 3.4 (2)

Polycystic ovary syndrome

Jara DJF, Ortega GC

Language: Spanish
References: 24
Page: 51-62
PDF size: 159.18 Kb.


ABSTRACT

Polycystic ovary syndrome is the most frequent endocrine disorder in young women. Due to its heterogenity, there is not a universal agreement about diagnostic criteria; however, the criteria established by Androgen Excess Society in 2009 are generally accepted. Its origin is still unknown, although there are evidences that it is multifactorial and has a strong multigenic genetic influence. The wide spectrum of symptoms and signs of polycystic ovary syndrome includes menstrual disorders, hirsutism, acne and polycystic ovary in ultrasound; however, the occurrence of these symptoms and signs is very variable, which difficult the diagnosis in some cases. The association with metabolic disorders is fully documented and is a concern in the integral management of patients with this syndrome. Among clinical considerations and recommendations, diseases with which differential diagnosis is made and the risk of diabetes, cardiovascular disease and endometrium cancer should be taken into account, as well as recommendations in life-style changes and treatment before different clinical settings, such as that of patients who do not desire to get pregnant, the use of ovulation inductors for treating infertility and insulin sensitizers in cases of insulin resistance.


REFERENCES

  1. Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 2004;191:713-717.

  2. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowickz DJ, Nestler JE. A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927-1932.

  3. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-191.

  4. Lane DE. Polycystic ovary syndrome and its differential diagnosis. Obstet Gynecol Surv 2006;61:125-135.

  5. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific, 1992;377-384.

  6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.

  7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.

  8. Murphy MK, Hall JE, Adams JM, Lee H, Welt CK. Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:3878-3884.

  9. Azziz R. Diagnosis of polycystic ovary syndrome: The Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91:781-785.

  10. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-488.

  11. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescents. Endocrinol Metab Clin North Am 2005;34:677-705.

  12. Vignesh JP, Mohan V. Polycystic ovary syndrome: A component of metabolic syndrome? J Postgrad Med 2007;53:128-134.

  13. Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol 2011;204:558.e1-6.

  14. Velling Magnussen L, Mumm H, Andersen M, Glintborg D. Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. Fertil Steril 2011;96:1275-1280.

  15. Mendoza N. Common genetic aspects between polycystic ovary syndrome and diabetes mellitus. Curr Diabetes Rev 2011;7:377-391.

  16. Hurd WW, Abdel-Rahman MY, Ismail SA, Abdellah MA, et al. Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertil Steril 2011;96:1043-1047.

  17. Sathyapalan T, Atkin S. Review topic on mechanisms in endocrinology: Recent advances in the cardiovascular aspects of polycystic ovary syndrome. Eur J Endocrinol 2011 Nov 17. [Epub ahead of print.]

  18. Lass N, Kleber M, Winkel K, Wunsch R, Reinehr T. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab 2011;96:3533-3540.

  19. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, et al. Metaanalysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741-760.

  20. Ortega-González C, Luna S, Hernández L, Crespo G, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1360-1365.

  21. Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, et al. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005;184:233-239.

  22. Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol 2010;22:466-476.

  23. He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reprod Biomed Online 2011;23:91-96.

  24. Jungheim ES, Odibo AO. Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents. Fertil Steril 2010;94:2659-2664.




2020     |     www.medigraphic.com